Search hospitals > Michigan > Chelsea
Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
Claim this profileChelsea, Michigan 48118
Global Leader in Lung Cancer
Global Leader in Breast Cancer
Conducts research for Breast cancer
Conducts research for Cancer
Conducts research for Non-Small Cell Lung Cancer
205 reported clinical trials
7 medical researchers
Summary
Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital is a medical facility located in Chelsea, Michigan. This center is recognized for care of Lung Cancer, Breast Cancer, Breast cancer, Cancer, Non-Small Cell Lung Cancer and other specialties. Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital is involved with conducting 205 clinical trials across 330 conditions. There are 7 research doctors associated with this hospital, such as Tareq Al Baghdadi, Christopher M. Reynolds, MD, Philip J. Stella, and Elie G. Dib.Area of expertise
1Lung Cancer
Global LeaderStage IV
Stage III
Stage II
2Breast Cancer
Global LeaderHER2 negative
Stage IV
ER positive
Top PIs
Tareq Al BaghdadiGenesys Hurley Cancer Institute8 years of reported clinical research
Expert in Cancer
Expert in Pancreatic Cancer
73 reported clinical trials
130 drugs studied
Christopher M. Reynolds, MDSaint Joseph Mercy Hospital2 years of reported clinical research
Expert in Lung Cancer
Expert in Non-Small Cell Lung Cancer
51 reported clinical trials
104 drugs studied
Philip J. StellaSaint Joseph Mercy Hospital5 years of reported clinical research
Expert in Lung Cancer
Expert in Non-Small Cell Lung Cancer
38 reported clinical trials
89 drugs studied
Elie G. DibGenesys Hurley Cancer Institute6 years of reported clinical research
Studies Multiple Myeloma
Studies Breast Cancer
38 reported clinical trials
105 drugs studied
Clinical Trials running at Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
Lung Cancer
Breast Cancer
Breast cancer
Esophageal cancer
Bladder Cancer
Ovarian Cancer
Non-Small Cell Lung Cancer
Multiple Myeloma
Pancreatic Cancer
Gastric cancer
Crizotinib
for Non-Small Cell Lung Cancer
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
Immunotherapy + Chemotherapy
for Non-Small Cell Lung Cancer
This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.
Recruiting2 awards Phase 327 criteria
Durvalumab
for Lung Cancer
This phase III trial compares durvalumab to the usual approach (patient observation) after surgery for the treatment of patients with early-stage non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. The usual approach for patients who are not in a study is to closely watch a patient's condition after surgery and to have regular visits with their doctor to watch for signs of the cancer coming back. Usually, patients do not receive further treatment unless the cancer returns. This study will help determine whether this different approach with durvalumab is better, the same, or worse than the usual approach of observation. Giving durvalumab may help patients live longer and prevent early-stage non-small cell lung cancer from coming back as compared to the usual approach.
Recruiting2 awards Phase 38 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital?
Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital is a medical facility located in Chelsea, Michigan. This center is recognized for care of Lung Cancer, Breast Cancer, Breast cancer, Cancer, Non-Small Cell Lung Cancer and other specialties. Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital is involved with conducting 205 clinical trials across 330 conditions. There are 7 research doctors associated with this hospital, such as Tareq Al Baghdadi, Christopher M. Reynolds, MD, Philip J. Stella, and Elie G. Dib.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.